Literature DB >> 33560350

Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?

Andrew B Lassman1, Timothy F Cloughesy2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33560350      PMCID： PMC7992892          DOI： 10.1093/neuonc/noab006

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  18 in total

1.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Authors:  Andrew B Lassman; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Katherine S Panageas
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.

Authors:  A Taliansky-Aronov; F Bokstein; I Lavon; T Siegal
Journal:  J Neurooncol       Date:  2006-07-20       Impact factor: 4.130

3.  A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.

Authors:  Hui K Gan; Mark A Rosenthal; Anthony Dowling; Renate Kalnins; Elizabeth Algar; Nicholas Wong; Angela Benson; Anne-Marie Woods; Lawrence Cher
Journal:  Neuro Oncol       Date:  2010-02-08       Impact factor: 12.300

4.  Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.

Authors:  Michael A Vogelbaum; Chen Hu; David M Peereboom; David R Macdonald; Caterina Giannini; John H Suh; Robert B Jenkins; Nadia N Laack; David G Brachman; Dennis C Shrieve; Luis Souhami; Minesh P Mehta
Journal:  J Neurooncol       Date:  2015-06-19       Impact factor: 4.130

5.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Authors:  Manmeet S Ahluwalia; Hao Xie; Saurabh Dahiya; Nooshin Hashemi-Sadraei; David Schiff; Paul G Fisher; Marc C Chamberlain; Susan Pannullo; Herbert B Newton; Cathy Brewer; Laura Wood; Richard Prayson; Paul Elson; David M Peereboom
Journal:  J Neurooncol       Date:  2014-12-23       Impact factor: 4.130

7.  Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.

Authors:  Esther J J Habets; Martin J B Taphoorn; Sylvie Nederend; Martin Klein; Daniel Delgadillo; Khê Hoang-Xuan; Andrew Bottomley; Anouk Allgeier; Tatjana Seute; Anja M M Gijtenbeek; Jan de Gans; Roelien H Enting; Cees C Tijssen; Martin J van den Bent; Jaap C Reijneveld
Journal:  J Neurooncol       Date:  2013-10-26       Impact factor: 4.130

8.  Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Authors:  Alissa A Thomas; Lauren E Abrey; Robert Terziev; Jeffrey Raizer; Nina L Martinez; Peter Forsyth; Nina Paleologos; Matthew Matasar; Craig S Sauter; Craig Moskowitz; Stephen D Nimer; Lisa M DeAngelis; Thomas Kaley; Sean Grimm; David N Louis; J Gregory Cairncross; Katherine S Panageas; Samuel Briggs; Geraldine Faivre; Nimish A Mohile; Jayesh Mehta; Philip Jonsson; Debyani Chakravarty; Jianjiong Gao; Nikolaus Schultz; Cameron W Brennan; Jason T Huse; Antonio Omuro
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

Review 9.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

Authors:  Michael Weller; Martin van den Bent; Matthias Preusser; Emilie Le Rhun; Jörg C Tonn; Giuseppe Minniti; Martin Bendszus; Carmen Balana; Olivier Chinot; Linda Dirven; Pim French; Monika E Hegi; Asgeir S Jakola; Michael Platten; Patrick Roth; Roberta Rudà; Susan Short; Marion Smits; Martin J B Taphoorn; Andreas von Deimling; Manfred Westphal; Riccardo Soffietti; Guido Reifenberger; Wolfgang Wick
Journal:  Nat Rev Clin Oncol       Date:  2020-12-08       Impact factor: 66.675

10.  CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.

Authors:  Kurt A Jaeckle; Karla V Ballman; Martin van den Bent; Caterina Giannini; Evanthia Galanis; Paul D Brown; Robert B Jenkins; J Gregory Cairncross; Wolfgang Wick; Michael Weller; Kenneth D Aldape; Jesse G Dixon; S Keith Anderson; Jane H Cerhan; Jeffrey S Wefel; Martin Klein; Stuart A Grossman; David Schiff; Jeffrey J Raizer; Frederick Dhermain; Donald G Nordstrom; Patrick J Flynn; Michael A Vogelbaum
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300
View more
  2 in total

1.  Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.

Authors:  Andrew B Lassman; Khê Hoang-Xuan; Mei-Yin C Polley; Alba A Brandes; J Gregory Cairncross; Johan M Kros; Lynn S Ashby; Martin J B Taphoorn; Luis Souhami; Winand N M Dinjens; Nadia N Laack; Mathilde C M Kouwenhoven; Karen L Fink; Pim J French; David R Macdonald; Denis Lacombe; Minhee Won; Thierry Gorlia; Minesh P Mehta; Martin J van den Bent
Journal:  J Clin Oncol       Date:  2022-06-22       Impact factor: 50.717

2.  Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation.

Authors:  Nayan Lamba; Malia McAvoy; Vasileios K Kavouridis; Timothy R Smith; Mehdi Touat; David A Reardon; J Bryan Iorgulescu
Journal:  Neurooncol Pract       Date:  2022-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.